Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : CEAPRO INC.----CZO -- Ignore unavailable to you. Want to Upgrade?

To: ciao888 who wrote (36)	8/21/2020 1:00:55 PM
From: ciao888	Respond to of 53

CZO Q2 results in summary: – Record second quarter sales of $4,666,000 compared to $3,054,000 for second quarter 2019, representing a 53% increase and highest quarterly sales in Company’s history – – R&D activities focused on the development of innovative delivery systems – – Net profit of $1,077,000 for Q2 2020 vs. net loss of $559,000 for Q2 2019 – – Cash generated from operations of $2,727,000 in 2020 vs $853,000 in 2019 – “We are extremely proud of our employees who worked tirelessly since the beginning of the year to deliver these excellent results despite the COVID-19 pandemic. Progress was made on all fronts from production operations with the largest volumes produced in Ceapro’s history to Research Engineering where the PGX group has successfully developed and optimized new products like yeast beta glucan as a potential inhalable therapeutic for COVID-19. As we continue to move forward and navigate operations during these unprecedented times, our focus remains on the health and safety of our associates, followed by business continuity,” stated Gilles Gagnon, M.Sc., MBA, President and CEO.